THE RESOLUTION OF THE EXPERT COUNCIL FOR TARGETED THERAPY OF RADIOIODINE REFRACTORY DIFFERENTIATED THYROID CANCER

THE RESOLUTION OF THE EXPERT COUNCIL FOR TARGETED THERAPY OF RADIOIODINE REFRACTORY DIFFERENTIATED THYROID CANCER

.

Bibliographic Details
Main Author:	. Expert Council
Format:	Article
Language:	Russian
Published:	ABV-press 2015-04-01
Series:	Опухоли головы и шеи
Online Access:	https://ogsh.abvpress.ru/jour/article/view/79

Similar Items

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: TENG Lisong, et al.
Published: (2023-05-01)

Progress in Re-differentiating Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: ZHANG Yaqi, et al.
Published: (2022-10-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

Interdisciplinary databank in oncoendocrinology: radioiodine refractory differentiated thyroid cancer
by: Pavel O. Rumyantsev, et al.
Published: (2022-04-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
by: June-Key Chung, et al.
Published: (2014-09-01)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
by: Genpeng Li, et al.
Published: (2018-11-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Systemic treatments for radioiodine-refractory thyroid cancers
by: Piaohong Chen, et al.
Published: (2024-10-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Resolution of the expert council on the question of strategy of tyrosine kinase inhibitor therapy initiation in differentiated thyroid cancer
by: article Editorial
Published: (2023-12-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Resolution of the expert council on the topic “Clinical practice of drug therapy of thyroid cancer”
by: article Editorial
Published: (2022-08-01)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
by: Chao Meng, et al.
Published: (2023-02-01)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
by: Miguel‐Ángel Berciano‐Guerrero
Published: (2022-10-01)

Current approaches to therapy for radioactive iodine therapy-resistant differentiated thyroid cancer: Expert council resolution on overall results
by: Editorial article
Published: (2015-11-01)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
by: Massimiliano Pacilio, et al.
Published: (2022-07-01)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
by: Yu-qing Sun, et al.
Published: (2022-11-01)

Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01)

Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit
by: L. J. Wirth, et al.
Published: (2023-03-01)

Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
by: Xiaoyu Ji, et al.
Published: (2022-08-01)

EFFICACY AND SAFETY OF MULTI-TARGETED KINASE INHIBITORS IN PROGRESSIVE, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCERS: A META-ANALYSIS
by: Mutahir A Tunio, et al.
Published: (2016-05-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

The management of metastatic radioiodine-refractory differentiated thyroid cancer requires an integrated approach including both directed and systemic therapies
by: Shamil D Cooray, et al.
Published: (2017-02-01)

mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer
by: Ju Yeon Pyo, et al.
Published: (2024-11-01)

The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases
by: Shenghong Zhang, et al.
Published: (2024-02-01)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
by: Zohreh Maghsoomi, et al.
Published: (2021-05-01)

Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma
by: Pepijn van Houten, et al.
Published: (2024-08-01)

Evaluation of Radioiodine Therapy in the Refractory Hyperthyroidism
by: Samira Rahimlou, et al.
Published: (2023-02-01)

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
by: Teresa Alonso‐Gordoa
Published: (2022-10-01)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
by: Javier Martínez‐Trufero
Published: (2022-10-01)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
by: Jaume Capdevila, et al.
Published: (2023-08-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Comparative proteomic analysis of differentiated thyroid carcinoma and radioiodine-refractory differentiated thyroid carcinoma based on iTRAQ technique
by: LI Yunjie, et al.
Published: (2019-12-01)

Oxidative stress and radioiodine treatment of differentiated thyroid cancer
by: Angelika Buczyńska, et al.
Published: (2021-08-01)

Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib
by: Chae A Kim, et al.
Published: (2024-04-01)